Efficacy News and Research

RSS
Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

Gilead Sciences receives EC approval for Viread to treat HIV-1 infected children

Gilead Sciences receives EC approval for Viread to treat HIV-1 infected children

Specific combination of two pharmaceutical substances show promise against multiple sclerosis

Specific combination of two pharmaceutical substances show promise against multiple sclerosis

Philips Healthcare, UH to showcase latest medical technology at Cleveland Medical Mart

Philips Healthcare, UH to showcase latest medical technology at Cleveland Medical Mart

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Grove professor to investigate personalized therapies against breast cancer

Grove professor to investigate personalized therapies against breast cancer

Tivantinib holds personalized therapy promise in HCC

Tivantinib holds personalized therapy promise in HCC

New therapeutic technique to repair and rebuild muscle for degenerative muscle disorders

New therapeutic technique to repair and rebuild muscle for degenerative muscle disorders

Accera commences clinical efficacy trial of AC-1204 for mild-to-moderate Alzheimer's disease

Accera commences clinical efficacy trial of AC-1204 for mild-to-moderate Alzheimer's disease

mRNA vaccines offer protection against influenza A virus infections in various animal models

mRNA vaccines offer protection against influenza A virus infections in various animal models

Allergies common in ADHD, tic disorder patients

Allergies common in ADHD, tic disorder patients

Rheumatoid arthritis patients adhere to both adalimumab, etanercept

Rheumatoid arthritis patients adhere to both adalimumab, etanercept

Temsirolimus effective for mRCC patients on hemodialysis

Temsirolimus effective for mRCC patients on hemodialysis

Bipolar I disorder has higher costs than other affective disorders

Bipolar I disorder has higher costs than other affective disorders

Citicoline not superior to placebo in treating traumatic brain injury

Citicoline not superior to placebo in treating traumatic brain injury

Australian TGA approves Genzyme’s AUBAGIO to treat relapsing forms of multiple sclerosis

Australian TGA approves Genzyme’s AUBAGIO to treat relapsing forms of multiple sclerosis

Prader-Willi children may receive relief from sleep disorders after adenotonsillectomy

Prader-Willi children may receive relief from sleep disorders after adenotonsillectomy

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.